SEARCH

SEARCH BY CITATION

References

  • 1
    Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplify for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004; 36: 808816.
  • 2
    Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus more frequent regimen improves daherence while maintaining viral suppression. HIV Clin Trials 2008; 9: 164176.
  • 3
    Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ. Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med 2008; 9: 667672.
  • 4
    Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clinical. Infect Dis 2009; 48: 484488.
  • 5
    Wright D, Rodriquez A, Godofsky E et al. Efficacy and safety of 48 weeks of effuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients. HIV Clin Trials 2008; 9: 7382.
  • 6
    Zajenverg R, Podsadecki T, Badal-Faesen S et al. Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1 infected subjects at 48 weeks. J Acquir Immune Defic Syndr 2010; 54: 143151.
  • 7
    Airoldi M, Zaccarelli M, Bisi L et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient 2010; 4: 115125.
  • 8
    Gianotti N, Galli L, Bocchiola B et al. Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy. HIV Med 2013; 14: 153160.
  • 9
    Sprenger HG, Langebeek N, Mulder PH et al. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naive patients: FREE randomized trial interim results. AIDS Patient Care STDS 2010; 24: 361366.
  • 10
    Knobel H, Alonso J, Casado JL et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA study. AIDS 2002; 16: 605613.
  • 11
    Woodcock A, Bradley C. Validation of the revised 10-item HIV treatment satisfaction questionnaire status version and new change version. Value Health 2006; 9: 320333.
  • 12
    Revicki DA, Sorensen S, Wu AW. Reliability and validity of physical and mental health summary scores from the Medical Outcome Study HIV Health Survey. Med Care 1998; 36: 126137.
  • 13
    Katlama C, Fenske S, Gazzard B et al. TRIZAL study: switching from successful HAART to Trizivir (abacvir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003; 4: 7986.
  • 14
    Markowitz M, Hill-Zabala C, Lang J et al. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48 weeks maintenance with abacavir/lamivudine/zidovudine alone in antiretriviral -naive HIV-1 infected patients. J Acquir Immune Defic Syndr 2005; 39: 257263.
  • 15
    Clotet B, Carmena J, Pulido F, Luque I, Rodriquez-Alcanatara F. Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral experienced patients. HIV Clin Trials 2004; 5: 3339.